Valuation: Devyser Diagnostics AB

Market Cap 1.04B 109M 94.41M 88.46M 80.68M 152M 10.39B 154M 407M 5.2B 409M 400M 17.35B P/E 2026 *
104x
P/E 2027 * 32.5x
Enterprise Value 993M 104M 90.14M 84.46M 77.04M 145M 9.92B 147M 388M 4.97B 391M 382M 16.57B EV / Sales 2026 *
4.04x
EV / Sales 2027 * 3.37x
Free-Float
70.22%
Yield 2026 *
-
Yield 2027 * -
1 day-2.28%
1 week-6.54%
Current month-7.32%
1 month+0.54%
3 months-34.55%
6 months-41.61%
Current year-45.50%
1 week 5.56
Extreme 5.56
6.06
1 month 5.36
Extreme 5.36
6.23
Current year 5.23
Extreme 5.23
10.56
1 year 5.23
Extreme 5.23
14.2
3 years 4.82
Extreme 4.82
14.2
5 years 4.82
Extreme 4.82
14.2
10 years 4.82
Extreme 4.82
14.2
Manager TitleAgeSince
Chief Executive Officer 59 2025-08-03
Director of Finance/CFO 43 2020-12-31
Chief Tech/Sci/R&D Officer 48 2024-01-31
Director TitleAgeSince
Chairman 57 2021-05-26
Director/Board Member 49 2020-12-31
Director/Board Member 72 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-6.54% - - 111M
-1.60%+1.76%+4.62%+14.41% 49.54B
-0.14%+4.03%+482.13%+584.43% 44.06B
-0.06%+9.62%+24.63%+81.63% 40.85B
-0.87%+2.40%+30.01%+9.95% 40.14B
-4.04%+8.72%+22.60%+48.00% 34.17B
-1.41%+1.57%+29.98%+123.68% 16.9B
+0.35%+4.61% - - 16.78B
-0.43%+1.13%+5.04%+20.83% 14B
+0.84%+9.07%+86.17%+32.60% 13.46B
Average -0.96%+4.74%+85.65%+114.44% 29.99B
Weighted average by Cap. -1.01%+5.04%+103.47%+136.92%

Financials

2026 *2027 *
Net sales 246M 25.76M 22.32M 20.91M 19.07M 35.86M 2.46B 36.41M 96.14M 1.23B 96.72M 94.62M 4.1B 298M 31.17M 27M 25.3M 23.08M 43.38M 2.97B 44.05M 116M 1.49B 117M 114M 4.96B
Net income 10.07M 1.05M 913K 856K 781K 1.47M 101M 1.49M 3.93M 50.35M 3.96M 3.87M 168M 31.97M 3.35M 2.9M 2.72M 2.48M 4.66M 319M 4.73M 12.5M 160M 12.57M 12.3M 533M
Net Debt -47.04M -4.93M -4.27M -4M -3.65M -6.86M -470M -6.96M -18.39M -235M -18.5M -18.1M -785M -39M -4.08M -3.54M -3.32M -3.02M -5.69M -390M -5.77M -15.24M -195M -15.34M -15M -650M
Logo Devyser Diagnostics AB
Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.
Employees
110
Date Price Change
26-08-12 €5.570 -2.28%
26-08-11 €5.700 -1.89%
26-08-10 €5.810 -2.19%
26-08-07 €5.940 +0.85%
26-08-06 €5.890 +1.03%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
41.80DKK
Average target price
65.94DKK
Spread / Average Target
+57.76%

Quarterly revenue - Rate of surprise